Bioventus BVS U.S. Segment — Adjusted research and development expense

Similar metrics at other companies

NCNOReportable Segment — Adjusted research and development expense

$25.44M-12.7%

PCTYReportable Segment — Research and Development Expense, Adjusted

$49.34M+14.1%

RELYReportable segment — Research and Development Expense, Adjusted

$58.11M+4.5%

FIVNReportable Segment — Research and Development Expense, Adjusted

$32.05M+16.9%

NETReportable Segment — Research And Development Expense, Adjusted

$104.05M+24.5%

DTReportable Segment — Adjusted research and development expenses

$103.43M+32.8%

FAQ

What is Bioventus's U.S. segment — adjusted research and development expense?

Bioventus (BVS) reported U.S. segment — adjusted research and development expense of $2.92M in Q2 2026.

How has Bioventus's U.S. segment — adjusted research and development expense changed year-over-year?

Bioventus's U.S. segment — adjusted research and development expense decreased by 0.1% year-over-year, from $2.92M to $2.92M.

What is the long-term trend for Bioventus's U.S. segment — adjusted research and development expense?

Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted research and development expense has grown at a -15.0% compound annual growth rate (CAGR), from $18.33M to $11.27M.

What does U.S. segment — adjusted research and development expense mean?

This metric quantifies the adjusted investment in innovation, clinical trials, and product development specifically allocated to the U.S. market. It reflects the company's commitment to advancing its portfolio of clinically differentiated orthopedic treatments.